REG - Immupharma PLC - Result of AGM

ImmuPharmaAnnouncement

12/06/2025 13:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250612:nRSL6274Ma&default-theme=true

RNS Number : 6274M  Immupharma PLC  12 June 2025

 

 

 
      12 June 2025

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

2025 RESULT OF ANNUAL GENERAL MEETING

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development
company, held its AGM earlier today. The Company is pleased to announce that
five of the six resolutions (Resolutions 1 - 5 inclusive) were duly passed by
shareholders, while the special resolution (which required approval of 75% of
votes cast to pass), was not approved. Details are contained in the table
below.

 

 Resolution                                                                       For         % For  Against     % Against  Withheld
 1. To receive the accounts of the Company for the year ended 31 December 2024    88,682,323  74     30,840,722  26         74,472
 together with the reports thereon of the directors and auditors of the Company
 2. To re-appoint Dr Tim Franklin as a director of the Company                    86,938,536  74     31,136,460  26         1,522,521
 3. To re-appoint Tim McCarthy as a director of the Company                       86,900,286  73     32,579,135  27         118,096
 4. To re-appoint Crowe UK LLP as Auditor of the Company                          86,901,988  76     27,981,718  24         4,713,811
 5. That the directors be authorised for the purpose of Section 551 of the        84,856,858  71     34,558,813  29         181,846
 Companies Act 2006 (the "Act") to allot shares on the basis as set out in the
 Notice of Meeting
 SPECIAL RESOLUTION                                                               84,812,828  71     34,602,843  29         181,846
 6. That, subject to the passing of Resolution 5 the directors be and they are
 hereby empowered pursuant to section 571 of the Act to allot equity securities
 as set out in the Notice of Meeting

 

 

As at the date of the AGM, the number of issued ordinary shares of the Company
was 499,723,932 shares, which was the total number of shares entitling the
holders to attend and vote for or against all resolutions. In accordance with
the Company's Articles of Association, every member has one vote for every
share held. Votes withheld are not votes in law and have not been counted in
the calculation of the proportion of vote "for" or "against" a
resolution. Proxy appointments which gave discretion to the Chairman have
been included in the "for" total.

Ends

 

 For further information please contact:

ImmuPharma PLC (www.immupharma.com (http://www.immupharma.com) )  +44 (0) 207 206 2650

 Tim McCarthy, Chief Executive Officer and Chairman

 Lisa Baderoon, Head of Investor Relations                         + 44 (0) 7721 413496

 SPARK Advisory Partners Limited (NOMAD)                           +44 (0) 203 368 3550

 Neil Baldwin

 Stanford Capital Partners (Joint Broker)                          +44 (0) 203 650 3650/51

 Patrick Claridge, Bob Pountney

 SI Capital (Joint Broker)                                         +44 (0) 1483 413500

 Nick Emerson

Notes to Editors

 

About ImmuPharma PLC

 

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that
discovers and develops peptide-based therapeutics. The Company's portfolio
includes novel peptide therapeutics for autoimmune diseases and
anti-infectives. The lead program, P140, is a unique non-immunosuppressive
peptide for the treatment of SLE (Systemic Lupus Erythematosus) and CIDP
(Chronic Idiopathic Demyelinating Polyneuropathy) and preclinical models
suggest therapeutic activity for many other autoimmune diseases.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk
(http://www.immupharma.co.uk)

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGDZGMVMZRGKZM